Table 3.

Differences between patient and death-censored allograft survival curves during a 10-year period after kidney transplantation (in months, with 95% confidence intervals)

AgeNo. of PatientsFirst Transplant RecipientsaSecond Transplant RecipientsaDifference between Second and First Transplant Recipientsb
All patients131,5182.1 [1.5 to 2.7]9.0 [5.4 to 12.6]6.8 [3.6 to 9.9]
18–40 yr, no diabetes27,67216.8 [15.7 to 18.0]24.7 [19.9 to 29.4]7.9 [4.2 to 11.4]
18–40 yr, diabetes11,3752.4 [0.6 to 4.2]4.4 [−14.0 to 22.5]2.4 [−0.7 to 18.3]
40–60 yr, no diabetes41,6712.3 [1.3 to 3.3]7.4 [1.7 to 13.0]5.0 [0.3 to 9.7]
40–60 yr, diabetes27,791−7.9 [−9.3 to −6.6]7.0 [−6.8 to 20.4]6.9 [−0.4 to 20.2]
>60 yr, no diabetes14,125−12.8 [−14.8 to −10.8]−9.7 [−23.4 to 4.2]0.0 [−0.1 to 4.0]
>60 yr, diabetes8884−20.8 [−23.6 to −17.9]−10.0 [−38.2 to 16.6]0.3 [0.0 to 16.5]
  • a The difference between patient survival and death-censored allograft survival curves are shown over 10 years after the date of first or second transplantation. In subgroups with positive values, the difference is equivalent to the duration of additional kidney replacement therapy (dialysis or transplantation) required. Negative values are seen when the average patient survival is less than average death-censored graft survival and are equivalent to the duration of allograft function lost because of the outcome of death with a functioning allograft. The values are calculated by subtracting the integral of the death-censored allograft survival curve from the integral of the patient survival curve over 10 years. This describes the area that is highlighted in gray on Figure 3.

  • b The difference between the duration of additional kidney replacement therapy (dialysis or transplantation) expected to be required by second transplant recipients compared with first transplant recipients is given in the last column. This is the difference in curves only when the average patient survival is longer than average graft survival. If the average patient survival is shorter than the graft survival then no additional kidney replacement therapy would be required and a value of 0 is adopted for these timepoints in the calculation.

  • All analyses are adjusted for age, sex, race, cause of ESKD, body mass index, medical insurance, congestive heart failure, peripheral vascular disease, cerebrovascular disease, atherosclerotic heart disease, chronic obstructive pulmonary disease, alcohol or drug dependencies, tobacco use, the inability to ambulate, transplant year, panel reactive antibody, and Kidney Donor Profile Index.